Clinical trials: Respiratory Distress of Newborn
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
ARDS, ARDS, Human
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
The purpose of this study is to evaluate safety, tolerability and efficacy of BZ371B in intubated patients with severe Acute Respiratory Distress Syndrome.
- Conditions
- ARDS, ARDS, Human, Pulmonary Disease
- Trial name
- NCT05384379
- Testing
- Inhaled BZ371B
- Where
- Brazil
- Volunteers
- 1 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)
Bronchopulmonary Dysplasia (BPD) is a multi-factorial disease process that is the end result of an immature, surfactant deficient lung that has been exposed to hyperoxia, mechanical ventilation and infection.
- Trial name
- NCT01473264
- Testing
- recombinant human CC10 (rhCC10)
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Clarassance, Inc.
Acute Respiratory Distress Syndrome
To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome
To evaluate the safety and initial efficacy of STSA-1002 injection in patients with acute respiratory distress syndrome.
- Trial name
- NCT06038916
- Testing
- STSA-1002 Injection
- Where
- 30 sites in China
- Volunteers
- 47 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Respiratory Distress Syndrome, Adult
Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.
- Trial name
- ONE-BRIDGE (NCT03807804)
- Testing
- HLCM051
- Where
- 29 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Healios K.K.
COVID-19 Pneumonia, COVID-19
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
COVID-19 has multiple facets including cytokine storm, thromboembolism and gelatinous secretions. It is known that oxygen exchange is the main problem in patients with COVID-19 and hypoxia is one of the most serious, in which…
- Conditions
- COVID-19 Pneumonia, COVID-19, Ventilator Associated Pneumonia, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05258682
- Testing
- Bromelains, Acetylcysteine
- Volunteers
- 30 people
- Sponsor
- Mucpharm Pty Ltd
COVID-19, Acute Respiratory Distress Syndrome
Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery
An informational evaluation of COVID-19 patients who receive low-level laser therapy in addition to a normal regimen of treatment for symptoms associate with COVID-19.
- Trial name
- NCT05258617
- Testing
- LLLT Photobiomodulation
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- Ward Photonics LLC
Lung Cancer Diagnosis
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine…
- Trial name
- PROACT-LUNG (NCT06122077)
- Testing
- blood draw
- Where
- 36 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Freenome Holdings Inc.
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience
Covid19, Novel Coronavirus Pneumonia
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius…
- Conditions
- Covid19, Novel Coronavirus Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- ARDOXSO (NCT04798716)
- Testing
- MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8), MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8), MSC-exosomes delivered intravenously every other day (8:8:8)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- AVEM HealthCare
Virus Diseases, Pneumonia
Universal Anti-Viral Vaccine for Healthy Elderly Adults
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection…
- Conditions
- Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia
- Trial name
- ALLOPRIME (NCT04441047)
- Testing
- AlloStim
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mirror Biologics, Inc.
Acute Respiratory Distress Syndrome, Lung Diseases
SILtuximab in Viral ARds (SILVAR) Study
This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or…
- Conditions
- Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections
- Trial name
- SILVAR (NCT04616586)
- Testing
- Siltuximab, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 555 people
- Sponsor
- RECORDATI GROUP
Sepsis
Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS
The goal of this clinical trial is to learn if YD0743 works to treat sepsis-associated acute respiratory distress syndrome (ARDS) in adult patients admitted to the Intensive Care Unit.
- Trial name
- NCT07413094
- Testing
- YD0743
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Respiratory Distress Syndrome, Newborn
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
A multicenter, double blind, randomized, single dose, active-controlled study to investigate the efficacy and safety of synthetic surfactant (CHF 5633) in comparison to porcine surfactant (Poractant alfa, Curosurf ®) in the…
- Trial name
- NCT02452476
- Testing
- CHF5633, Poractant alfa
- Where
- 23 sites in United States
- Volunteers
- 123 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Lung Injury, Acute Respiratory Distress Syndrome
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
The purpose of this study was to assess the safety, tolerability and preliminary efficacy of FP-1201 (Interferon Beta) in patients with Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT00789685
- Testing
- Interferon Beta
- Where
- 8 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- Faron Pharmaceuticals Ltd
Severe to Critical COVID 19 With Associated ARDS
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
- Trial name
- NCT04750278
- Testing
- FP-025 100 mg, FP-025 300 mg
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Corona Virus Infection, COVID-19
Zofin (Organicell Flow) for Patients With COVID-19
The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
- Conditions
- Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04384445
- Testing
- Zofin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ZEO ScientifiX, Inc.
Acute Respiratory Distress Syndrome, Noninvasive Ventilation
Helmet vs Face Mask in Patients With Acute Respiratory Distress Syndrome
The objective of this study is to evaluate the efficacy of noninvasive ventilation with helmet in reducing endotracheal intubation rates in comparison with Noninvasive Ventilation (NIV) facemask among patients with Acute…
- Conditions
- Acute Respiratory Distress Syndrome, Noninvasive Ventilation, Corona Virus Disease, Acute Respiratory Failure
- Trial name
- NCT04507802
- Testing
- Non invasive ventilation via helmet
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Respiratory Distress Syndrome, Acute
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis.
- Trial name
- NCT05795465
- Testing
- GEn-1124
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- GEn1E Lifesciences
Acute Respiratory Distress Syndrome (ARDS), ARDS
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT06701656
- Testing
- Cohort C: bevacizumab
- Where
- 41 sites in United States
- Volunteers
- 200 people
- Sponsor
- PPD Development, LP